Advertisement

Long vs Short Acting Testosterone Treatments: A Look at the Risks

Published:November 27, 2022DOI:https://doi.org/10.1016/j.urology.2022.11.016
      Prescriptions for testosterone therapy (TT) to treat testosterone deficiency have increased in recent years. The purpose of this review was to evaluate the risks of several treatment modalities to better counsel patients. Both short-acting and long-acting TT has been shown to restore normal serum testosterone levels and improve symptoms of testosterone deficiency. Short-acting pharmacology mimics normal physiology more closely than long-acting TT but requires multiple doses per day. Long-acting TT has a higher rate of patient adherence but is more likely to create supraphysiologic serum testosterone and pathologic sequelae.

      Abbreviations:

      TT (Testosterone Therapy), T (Testosterone), IM (Intramuscular), SQ (Subcutaneous)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Handelsman DJ.
        Androgen misuse and abuse.
        Best Pract Res Clin Endocrinol Metab. 2011; 25: 377-389https://doi.org/10.1016/j.beem.2010.09.005
        • Handelsman DJ.
        The illusory case for treatment of an invented disease.
        Front Endocrinol. 2022; 12 (682620-682620)https://doi.org/10.3389/fendo.2021.682620
        • Rostom M
        • Ramasamy R
        • Kohn TP
        History of testosterone therapy through the ages.
        Int J Impot Res. 2022; 34: 623-625
        • Handelsman DJ.
        Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse.
        Med J Aust. 2013; 199: 548-551
        • Baillargeon J
        • Kuo YF
        • Westra JR
        • Urban RJ
        • Goodwin JS.
        Testosterone prescribing in the United States, 2002-2016.
        JAMA. 2018; 320: 200-202https://doi.org/10.1001/jama.2018.7999
        • Shahinyan RH
        • Amighi A
        • Carey AN
        • et al.
        Direct-to-consumer internet prescription platforms overlook crucial pathology found during traditional office evaluation of young men with erectile dysfunction.
        Urology. 2020; 143: 165-172https://doi.org/10.1016/j.urology.2020.03.067
        • Mulhall JP
        • Trost LW
        • Brannigan RE
        • et al.
        Evaluation and management of testosterone deficiency: AUA guideline.
        J Urol. 2018; 200: 423-432
        • Lunenfeld B
        • Mskhalaya G
        • Zitzmann M
        • et al.
        Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.
        Aging Male. 2015; 18: 5-15https://doi.org/10.3109/13685538.2015.1004049
        • Bhasin S
        • Pencina M
        • Jasuja GK
        • et al.
        Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts.
        J Clin Endocrinol Metab. 2011; 96: 2430-2439https://doi.org/10.1210/jc.2010-3012
        • Shin YS
        • Park JK.
        The optimal indication for testosterone replacement therapy in late onset hypogonadism.
        J Clin Med. 2019; 8,https://doi.org/10.3390/jcm8020209
        • Bhasin S
        • Brito JP
        • Cunningham GR
        • et al.
        Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline.
        J Clin Endocrinol Metab. 2018; 103: 1715-1744https://doi.org/10.1210/jc.2018-00229
        • Hackett G
        • Kirby M
        • Edwards D
        • et al.
        British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice.
        J Sex Med. 2017; 14: 1504-1523https://doi.org/10.1016/j.jsxm.2017.10.067
        • Salter CA
        • Mulhall JP.
        Guideline of guidelines: testosterone therapy for testosterone deficiency.
        BJU Int. 2019; 124: 722-729
        • Snyder PJ
        • Bhasin S
        • Cunningham GR
        • et al.
        Lessons from the testosterone trials.
        Endocr Rev. 2018; 39: 369-386
        • Bassil N
        • Alkaade S
        • Morley JE.
        The benefits and risks of testosterone replacement therapy: a review.
        Ther Clin Risk Manage. 2009; 5: 427
        • Wang C
        • Harnett M
        • Dobs AS
        • Swerdloff RS.
        Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: An 84-week phase III clinical trial.
        J Androl. 2010; 31: 457-465
        • Glueck CJ
        • Wang P.
        Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.
        Metabolism. 2014; 63: 989-994https://doi.org/10.1016/j.metabol.2014.05.005
        • Pastuszak AW
        • Rodriguez KM
        • Nguyen TM
        • Khera M.
        Testosterone therapy and prostate cancer.
        Transl Androl Urol. Dec 2016; 5: 909-920https://doi.org/10.21037/tau.2016.08.17
        • Layton JB
        • Kim Y
        • Alexander GC
        • Emery SL.
        Association between direct-to-consumer advertising and testosterone testing and initiation in the United States, 2009-2013.
        JAMA. 2017; 317: 1159-1166
        • Masterson TA
        • Turner D
        • Vo D
        • et al.
        The effect of longer-acting vs shorter-acting testosterone therapy on follicle stimulating hormone and luteinizing hormone.
        Sex Med Rev. 2021; 9: 143-148
        • Westfield G
        • Kaiser UB
        • Lamb DJ
        • Ramasamy R
        Short-acting testosterone: more physiologic?.
        Front Endocrinol. 2020; 11: 572465
        • Aschenbrenner DS.
        First oral testosterone product now available.
        AJN Am J Nurs. 2019; 119: 22-23
        • Barbonetti A
        • D'Andrea S
        • Francavilla S
        Testosterone replacement therapy.
        androl. 2020; 8: 1551-1566
        • Rogol A
        • Tkachenko N
        • Bryson N.
        Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
        Androl. 2016; 4: 46-54
      1. NATESTO [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; 2015. https://www.endo.com/File%20Library/Products/Prescribing%20Information/Natesto_prescribing_information.html

        • Ramasamy R
        • Masterson TA
        • Best JC
        • et al.
        Effect of natesto on reproductive hormones, semen parameters and hypogonadal symptoms: a single center, open label, single arm trial.
        J Urol. 2020; 204: 557-563
        • Wang C
        • Ilani N
        • Arver S
        • McLachlan RI
        • Soulis T
        • Watkinson A.
        Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men.
        Clin Endocrinol (Oxf). 2011; 75: 836-843
        • Dobs AS
        • McGettigan J
        • Norwood P
        • Howell J
        • Waldie E
        • Chen Y.
        A novel testosterone 2% gel for the treatment of hypogonadal males.
        J Androl. 2012; 33: 601-607
        • Nackeeran S
        • Kohn T
        • Gonzalez D
        • White J
        • Ory J
        • Ramasamy R.
        The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network meta-analysis of randomized trials.
        J Urol. 2022; 207: 44-51
        • Stahlman J
        • Britto M
        • Fitzpatrick S
        • et al.
        Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
        Curr Med Res Opin. 2012; 28: 291-301https://doi.org/10.1185/03007995.2011.652732
        • Kim ED
        • McCullough A
        • Kaminetsky J.
        Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.
        BJU Int. 2016; 117: 677-685
        • Raynaud J-P
        • Legros J-J
        • Rollet J
        • et al.
        Efficacy and safety of a new testosterone-in-adhesive matrix patch applied every 2 days for 1 year to hypogonadal men.
        J Steroid Biochem Mol Biol. 2008; 109: 168-176
      2. ANDRODERM [package insert]. Salt Lake City, UT: Watson Laboratories; 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020489s025lbl.pdf

        • Swerdloff RS
        • Dudley RE.
        A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
        Ther Adv Urol. 2020; 121756287220937232
        • Ohlander SJ
        • Varghese B
        • Pastuszak AW.
        Erythrocytosis following testosterone therapy.
        Sex Med Rev. 2018; 6: 77-85https://doi.org/10.1016/j.sxmr.2017.04.001
        • DelConte A
        • Papangkorn K
        • Kim K
        • et al.
        A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism.
        Andrology. 2022; 10: 669-676https://doi.org/10.1111/andr.13153
        • Kaminetsky J
        • Jaffe JS
        • Swerdloff RS.
        Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: a phase II study.
        Sex Med. 2015; 3: 269-279https://doi.org/10.1002/sm2.80
        • Kaminetsky JC
        • Moclair B
        • Hemani M
        • Sand M.
        A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism.
        J Sex Med. 2011; 8: 1186-1196
        • Kaminetsky JC
        • McCullough A
        • Hwang K
        • Jaffe JS
        • Wang C
        • Swerdloff RS.
        A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector.
        J Urol. 2019; 201: 587-594https://doi.org/10.1016/j.juro.2018.09.057
        • Gittelman M
        • Jaffe JS
        • Kaminetsky JC.
        Safety of a new subcutaneous testosterone enanthate auto-injector: results of a 26-week study.
        J Sex Med. 2019; 16: 1741-1748https://doi.org/10.1016/j.jsxm.2019.08.013
        • Figueiredo MG
        • Gagliano-Jucá T
        • Basaria S.
        Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option.
        J Clin Endocrinol Metab. 2022; 107: 614-626
        • Choi EJ
        • Xu P
        • Barham D
        • El-Khatib FM
        • Yafi FA
        • Kavoussi PK.
        Comparison of outcomes for hypogonadal men treated with intramuscular testosterone cypionate versus subcutaneous testosterone enanthate.
        J Urol. 2022; 207: 677-683https://doi.org/10.1097/JU.0000000000002301
        • Elliott J
        • Kelly SE
        • Millar AC
        • et al.
        Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis.
        BMJ open. 2017; 7e015284
        • Snyder PJ
        • Bhasin S
        • Cunningham GR
        • et al.
        Effects of testosterone treatment in older men.
        N Engl J Med. 2016; 374: 611-624
        • Ory J
        • Diaz P
        • Rivero M-J
        • et al.
        Comparing Rates of Polycythemia in Hypogonadal Men Using Nasal Testosterone Gel Versus Intramuscular Testosterone: Update of a Randomized Clinical Trial.
        Eur Urol Focus. 2022; https://doi.org/10.1016/j.euf.2022.09.001
        • Ory J
        • Nackeeran S
        • Balaji NC
        • Hare JM
        • Ramasamy AR.
        Secondary polycythemia in men receiving testosterone therapy increases risk of major adverse cardiovascular events and venous thromboembolism in the first year of therapy.
        J Urol. 2022; 207: 1295-1301https://doi.org/10.1097/ju.0000000000002437
        • Yassin A
        • AlRumaihi K
        • Alzubaidi R
        • Alkadhi S
        • Al Ansari A.
        Testosterone, testosterone therapy and prostate cancer.
        Aging Male. 2019; 22: 219-227
        • Zhang X
        • Huang K
        • Saad F
        • Haider KS
        • Haider A
        • Xu X.
        Testosterone therapy reduces cardiovascular risk among hypogonadal men: a prospective cohort study in Germany.
        Androgens: Clin Res Ther. 2021; 2: 64-72
        • McBride JA
        • Coward RM.
        Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use.
        Asian J Androl. 2016; 18: 373-380https://doi.org/10.4103/1008-682X.173938
        • Gu Y
        • Liang X
        • Wu W
        • et al.
        Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men.
        J Clin Endocrinol Metab. 2009; 94: 1910-1915
        • MALE MFTRO
        Contraceptive efficacy of testosterone-induced azoospermia in normal men.
        Lancet North Am Ed. 1990; 336: 955-959
        • Nieschlag VII, E
        If testosterone, which testosterone? Which androgen regimen should be used for supplementation in older men? Formulation, dosing, and monitoring issues.
        J Clin Endocrinol Metab. 1998; 83: 3443-3448
        • Behre HM
        • Nieschlag E
        Comparative pharmacokinetics of testosterone esters. Springer. 1998;2: 329-348
        • Middleton T
        • Turner L
        • Fennell C
        • et al.
        Complications of injectable testosterone undecanoate in routine clinical practice.
        Eur J Endocrinol. 2015; 172: 511-517https://doi.org/10.1530/EJE-14-0891
        • Pastuszak AW
        • Hu Y
        • Freid JD.
        Occurrence of pulmonary oil microembolism after testosterone undecanoate injection: a postmarketing safety analysis.
        Sex Med. 2020; 8: 237-242https://doi.org/10.1016/j.esxm.2020.01.009
        • Carrasquillo R
        • Chu K
        • Ramasamy R.
        Novel therapy for male hypogonadism.
        Curr Urol Rep. 2018; 19: 63https://doi.org/10.1007/s11934-018-0816-x
        • Seftel A.
        Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
        Int J Impot Res. 2007; 19: 2-24https://doi.org/10.1038/sj.ijir.3901366
        • Kelleher S
        • Turner L
        • Howe C
        • Conway A
        • Handelsman D.
        Extrusion of testosterone pellets: a randomized controlled clinical study.
        Clin Endocrinol-Oxford. 1999; 51: 469-472
        • Handelsman DJ
        • Mackey MA
        • Howe C
        • Turner L
        • Conway AJ.
        An analysis of testosterone implants for androgen replacement therapy.
        Clin Endocrinol (Oxf). 1997; 47: 311-316https://doi.org/10.1046/j.1365-2265.1997.2521050.x
        • McCullough A.
        A review of testosterone pellets in the treatment of hypogonadism.
        Curr Sex Health Rep. 2014; 6: 265-269.https://doi.org/10.1007/s11930-014-0033-7
        • Elliott J
        • Kelly SE
        • Millar AC
        • et al.
        Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis.
        BMJ Open. 2017; 7e015284https://doi.org/10.1136/bmjopen-2016-015284
        • Gurayah AA
        • Mason MM
        • Masterson JM
        • Kargi AY
        • Ramasamy R.
        U-shaped association between prevalence of secondary hypogonadism and body mass index: a retrospective analysis of men with testosterone deficiency.
        Int J Impot Res. 2022; : 1-4
        • Kim SD
        • Cho KS.
        Obstructive Sleep Apnea and Testosterone Deficiency.
        World J Mens Health. 2019; 37: 12-18https://doi.org/10.5534/wjmh.180017
        • White J
        • Petrella F
        • Ory J.
        Testosterone therapy and secondary erythrocytosis.
        Int J Impot Res. 2022; : 1-5